Omnicell enters $350M revolver, down from $500M; includes incremental facility

OMNICELL, INC.

Five-year revolving credit facility of $350M, downsized from $500M in prior agreement.
Uncommitted incremental loan facility up to $250M plus 100% of adjusted EBITDA.
Maturity on fifth anniversary with springing maturity tied to 0.25% convertible notes due 2025.
Proceeds for working capital, potential acquisitions, and general corporate purposes.
Option within 18 months to adopt ESG amendment adjusting margins based on sustainability KPIs.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OMNICELL, INC. amended Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association valued at $350,000,000 five-year revolving credit facility, letter of credit sub-limit $15,000,000, swing line (effective 2023-10-10).

Action: amendment
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association
Value: $350,000,000 five-year revolving credit facility, letter of credit sub-limit $15,000,000, swing line
Effective: 2023-10-10

Exact text from the filing

On October 10, 2023 (the “Effective Date”), Omnicell, Inc. (the “Company”), as borrower, entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

OMNICELL, INC. filing history →

Source: SEC EDGAR

accession 0000926326-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.